Granahan Investment Management LLC Has $5.21 Million Stock Holdings in Xencor, Inc. (NASDAQ:XNCR)

Granahan Investment Management LLC grew its holdings in Xencor, Inc. (NASDAQ:XNCRGet Rating) by 59.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 195,338 shares of the biopharmaceutical company’s stock after buying an additional 72,503 shares during the quarter. Granahan Investment Management LLC owned 0.33% of Xencor worth $5,212,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. raised its stake in shares of Xencor by 0.5% in the 1st quarter. BlackRock Inc. now owns 9,385,217 shares of the biopharmaceutical company’s stock valued at $250,396,000 after buying an additional 50,387 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Xencor by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 6,393,982 shares of the biopharmaceutical company’s stock worth $170,592,000 after purchasing an additional 69,206 shares in the last quarter. Loomis Sayles & Co. L P increased its position in shares of Xencor by 6.7% during the 1st quarter. Loomis Sayles & Co. L P now owns 1,818,057 shares of the biopharmaceutical company’s stock worth $48,506,000 after purchasing an additional 113,818 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Xencor by 9.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 926,709 shares of the biopharmaceutical company’s stock worth $24,727,000 after purchasing an additional 81,482 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. grew its holdings in Xencor by 5.5% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 876,981 shares of the biopharmaceutical company’s stock worth $23,397,000 after acquiring an additional 45,642 shares during the last quarter. Institutional investors and hedge funds own 99.28% of the company’s stock.

Analysts Set New Price Targets

XNCR has been the topic of a number of research analyst reports. Piper Sandler decreased their price objective on shares of Xencor from $66.00 to $42.00 and set an “overweight” rating on the stock in a report on Monday, May 23rd. StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Thursday, August 4th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $50.00 price objective on shares of Xencor in a report on Wednesday, July 6th. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Xencor presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.83.

Xencor Trading Up 2.3 %

Shares of NASDAQ XNCR opened at $25.90 on Friday. The firm has a market capitalization of $1.55 billion, a PE ratio of 76.18 and a beta of 0.62. Xencor, Inc. has a 1 year low of $19.35 and a 1 year high of $43.61. The firm’s 50-day moving average is $29.20 and its 200-day moving average is $27.06.

Xencor (NASDAQ:XNCRGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.12). Xencor had a return on equity of 3.15% and a net margin of 7.77%. The firm had revenue of $30.18 million for the quarter, compared to the consensus estimate of $34.35 million. As a group, equities research analysts anticipate that Xencor, Inc. will post -1.74 earnings per share for the current fiscal year.

Xencor Company Profile

(Get Rating)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Featured Stories

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.